Evidence map›Paper›PMID 19521957›Full record

ArticleInternational journal of cancer2009

Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays.

Meng Chen, Yuanqing Ye, Hushan Yang, Pheroze Tamboli, Surena Matin, Nizar M Tannir, Christopher G Wood, Jian Gu, Xifeng Wu

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in International journal of cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01791387 (Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study), which is not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01791387 phase2unknown statusnot on this mapstarted 2012, after this paper: background citation

Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study

TypeinterventionalSponsorAuckland District Health BoardRan2012 to 2015Enrolled30ConditionsClear Cell Renal Cell CarcinomaArmsDovitinib
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 81 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine.Kidney cancer journal : official journal of the Kidney Cancer Association · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Thyroid Hormones as Renal Cell Cancer Regulators.Journal of signal transduction · 2016
    Review
  17. Article
  18. The structure and function of NKAIN2-a candidate tumor suppressor.International journal of clinical and experimental medicine · 2015
    Review
  19. Chromosomal imbalances revealed in primary renal cell carcinomas by comparative genomic hybridization.International journal of clinical and experimental pathology · 2015
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Meng ChenDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yuanqing Ye
Hushan Yang
Pheroze Tamboli
Surena Matin
Nizar M Tannir
Christopher G Wood
Jian Gu
Xifeng Wu
The University of Texas MD Anderson Cancer Center · US

Funding

Genetic Instability & Risk for Esophageal CarcinomaR01CA111922 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2008 to 2012
$2.9M
Genetic Susceptibility Modifiers in Renal Cell CarcinomaR01CA098897 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WU, XIFENG · 2003 to 2007
$2.5M
NCI NIH HHS CA098897NCI NIH HHS R01 CA098897NCI NIH HHS R01 CA111922
6 · The paper itself

Abstract

The identification of genetic aberrations may help understand the mechanisms of tumorigenesis and has important implications in diagnosis, prognosis and treatment. We applied Illumina's 317K high-density single nucleotide polymorphism (SNP) arrays to profile chromosomal aberrations in clear cell renal cell carcinoma (ccRCC) from 80 patients and analyzed the association of LOH/amplification events with clinicopathological characteristics and telomere length. The most common loss of heterozygosity (LOH) were 3p (69 cases) including 38 whole 3p arm losses, 30 large fragment LOH (spanning 3p21-36), and 1 interstitial LOH (spanning 3p12-14, 3p21-22, 3p24.1-24.2 and 3p24.3), followed by chromosome losses at 8p12-pter, 6q23.3-27, 14q24.1-qter, 9q32-qter, 10q22.3-qter, 9p13.3-pter, 4q28.3-qter and 13q12.1-21.1. We also found several smallest overlapping regions of LOH that contained tumor suppressor genes. One smallest LOH in 8p12 had a size of 0.29 Mb and only contained one gene (NRG1). The most frequent chromosome gains were at 5q (32 cases), including 10 whole 5q amplification, 21 large amplifications encompassing 5q32-ter and 1 focal amplification in 5q35.3 (0.42 Mb). The other common chromosome gains were 1q25.1-qter, 7q21.13-qter, 8q24.12-qter and whole 7p arm. Significant associations of LOH at 9p, 9q, 14q and 18q were observed with higher nuclear grade. Significant associations with tumor stage were observed for LOH at 14q, 18p and 21q. Finally, we found that tumors with LOH at 2q, 6p, 6q, 9p, 9q and 17p had significantly shorter telomere length than those without LOH. This is the first study to use Illumina's SNP-CGH array that provides a close estimate of the size and frequency of chromosome LOH and amplifications of ccRCC. The identified regions and genes may become diagnostic and prognostic biomarkers as well as potential targets of therapy.

Indexed as

Chromosome AberrationsGenome, HumanOligonucleotide Array Sequence AnalysisCarcinoma, Renal CellComparative Genomic HybridizationFemaleGene Expression ProfilingHumansKidney NeoplasmsMaleMiddle AgedPolymorphism, Single NucleotideTelomere

Identifiers

PMID19521957
PMCPMC2768265
OpenAlexW2087423733

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.